Clinical & Histopathological Features of Ocular Surface Squamous Neoplasia

Purpose: To study various clinical and histopathological features of ocular surface squamous neoplasia. Ocular surface squamous neoplasia (OSSN) represents a rare spectrum of disease ranging from mild dysplasia to carcinoma in situ to invasive squamous cell carcinoma of the ocular surface involving the conjunctiva and the cornea, occurring usually in the interpalpebral area, mostly at the limbus. Methods And Materials: This study is conducted on 14 patients who underwent surgical excision for histopathologically proven cases of ocular surface squamous neoplasia (OSSN) in deptt of ophthalmology of MLB medical college Jhansi over a period of 6 months. In each case a complete medical and surgical taken, ocular examination including location, extent and clinical history was appearance of the lesion was done. The lesions were surgically excised keeping a safe margin of 2-3 mm of normal appearing conjunctiva and histopathological studies were performed. Results: The commonest age group involved in our series was 51-60 years accounting for 83.3%.The mean age being 54.91 years. Male and female were affected in equal ratio. Mean duration of symptoms was 7.79 months. Mean follow up was 20.8 months. All patients had unilateral tumor with equal involvement of right and left eyes. Interpalpebral involvement was seen in all patients. Temporal quadrant was most commonly affected (66%). In 7 patients (50%). Lesions were confined to conjunctiva and in rest 7 patients (50%) growth extended to cornea. Morphologically (41.6%) patients were leucoplakic, (33.3%) patients were papilomatous,2 (16.6%) patients were gelatinous and 1(8.3%) patients were cystic. Impression cytology was done in 8 patients (75%) and was co-related with histopathology. Systemic predisposing factors like xeroderma pigmentosa was seen in 1(4.16%) patients and AIDS in 2(8.33%) patients. Recurrence of lesions was seen in 2 patients (8.33%), out of which one underwent resurgery and other was treated with topical mytomycin.